REGENXBIO Inc. (RGNX)
NASDAQ: RGNX · Real-Time Price · USD
10.08
-0.47 (-4.45%)
At close: May 11, 2026, 4:00 PM EDT
10.17
+0.09 (0.89%)
Pre-market: May 12, 2026, 8:33 AM EDT
REGENXBIO Revenue
In the year 2025, REGENXBIO had annual revenue of $170.44M with 104.54% growth. REGENXBIO had revenue of $30.34M in the quarter ending December 31, 2025, with 43.00% growth.
Revenue (ttm)
$170.44M
Revenue Growth
+104.54%
P/S Ratio
3.05
Revenue / Employee
$459,410
Employees
371
Market Cap
520.30M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 170.44M | 87.11M | 104.54% |
| Dec 31, 2024 | 83.33M | -6.91M | -7.66% |
| Dec 31, 2023 | 90.24M | -22.48M | -19.94% |
| Dec 31, 2022 | 112.72M | -357.62M | -76.03% |
| Dec 31, 2021 | 470.35M | 315.78M | 204.30% |
| Dec 31, 2020 | 154.57M | 119.33M | 338.70% |
| Dec 31, 2019 | 35.23M | -183.27M | -83.88% |
| Dec 31, 2018 | 218.51M | 208.11M | 2,002.42% |
| Dec 31, 2017 | 10.39M | 5.80M | 126.48% |
| Dec 31, 2016 | 4.59M | -3.00M | -39.52% |
| Dec 31, 2015 | 7.59M | 1.47M | 23.99% |
| Dec 31, 2014 | 6.12M | 33.00K | 0.54% |
| Dec 31, 2013 | 6.09M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| MiMedx Group | 389.42M |
| Valneva SE | 205.07M |
| 4D Molecular Therapeutics | 88.24M |
| Prothena Corporation | 57.94M |
| Adlai Nortye | 5.00M |
| ProKidney | 893.00K |
RGNX News
- 5 days ago - REGENXBIO Announces Presentations at the American Society of Gene & Cell Therapy 2026 Annual Meeting - PRNewsWire
- 6 days ago - REGENXBIO to Host Webcast on May 14 to Discuss Topline Results from Pivotal Trial of RGX-202 for Duchenne Muscular Dystrophy - PRNewsWire
- 6 weeks ago - SUEWALLST, LLP: INSTITUTIONAL RGNX HOLDERS FACE PORTFOLIO LOSSES FROM GENE THERAPY FRAUD - PRNewsWire
- 6 weeks ago - Shareholders Sue RGNX Over Gene Therapy Study Claims - TipRanks
- 2 months ago - Regenxbio's Duchenne gene therapy shows improved muscle function in trial - Reuters
- 2 months ago - Regenxbio reports interim data from Phase I/II AFFINITY DUCHENNE trial - TheFly
- 2 months ago - REGENXBIO REPORTS NEW POSITIVE INTERIM DATA FROM PHASE I/II AFFINITY DUCHENNE® TRIAL OF RGX-202 - PRNewsWire
- 2 months ago - REGENXBIO Transcript: Barclays 28th Annual Global Healthcare Conference - Transcripts